Vast Therapeutics
  • Home
  • About
    • Company Overview
    • Our Team
    • Scientific Advisory Board
    • Careers
  • Technology
    • Nitric Oxide
    • Need for Antibiotic Alternatives
    • Broad Spectrum Efficacy
  • Applications
    • Cystic Fibrosis
    • NTM Lung Disease
    • Other Targets
  • Media
  • Investors
Picture

Leveraging our proprietary nitric oxide technology to address the growing global threat of antibiotic-resistant pathogens.

​About Us

Vast Therapeutics is a preclinical stage biotechnology company focused on harnessing the unique properties of nitric oxide to treat drug-resistant microbial infections.
​
​
Learn More

​Technology

​Vast Therapeutics’ patented nitric oxide technology is being used to create a new class of antibiotic alternative compounds that deliver broad-spectrum antimicrobial activity without the risk of developing drug resistance common to traditional antibiotics.
Learn More

​Investors

Vast Therapeutics is committed to bringing breakthrough therapies to market that address the growing need for novel compounds to treat emerging and antibiotic-resistant respiratory infections.  

​​
Learn More

RECENT NEWS

KNOW Bio Announces Breakthrough Nitric Oxide Discovery to Combat COVID-19

Sep 10, 2020

​​Research Triangle Park, N.C. (September 10, 2020) – KNOW Bio, LLC has generated the first definitive evidence that nitric oxide (NO) can inhibit viral reproduction of SARS-CoV-2, the human coronavirus that causes COVID-19. Nitric oxide is a molecule produced naturally by the body to regulate blood flow, control inflammation, and defend against invading microorganisms.
Learn More
Vast Therapeutics Announces BIOC11 testing results for Nontuberculous Mycobacteria (NTM) in Animal Model

Oct 22, 2019

​DURHAM, N.C., Oct. 22, 2019 -- Vast Therapeutics, Inc., a subsidiary of KNOW Bio, LLC, announces that BIOC11 eradicated 99% of the Nontuberculous Mycobacteria (NTM) in an in vivo animal model of infection; this data will be presented at the National Cystic Fibrosis Conference to be held in Nashville, Tennessee from October 31 to November 2, 2019.
Learn More
​Vast Therapeutics Receives Qualified Infectious Disease Product Status for BIOC11

Oct 8, 2019

DURHAM, NC – October 8, 2019 – Vast Therapeutics, Inc., a subsidiary of KNOW Bio, LLC, today announced that another of its drug candidates, BIOC11, has been designated as a “Qualified Infectious
Disease Product” (QIDP) by the U.S. Food and Drug Administration. 
​

Learn More
Picture

Address

​4222 Emperor Blvd. Suite 470
​Durham, NC 27703

Contact Us

info@vasttherapeutics.com

Sector

Biopharmaceutical

Industry

​Biotechnology

    Sign Up for Email Alerts

Submit
​Forward-Looking Statement | Privacy | Terms of Use | Site Map
​Copyright © 2021 Vast Therapeutics - All Rights Reserved
  • Home
  • About
    • Company Overview
    • Our Team
    • Scientific Advisory Board
    • Careers
  • Technology
    • Nitric Oxide
    • Need for Antibiotic Alternatives
    • Broad Spectrum Efficacy
  • Applications
    • Cystic Fibrosis
    • NTM Lung Disease
    • Other Targets
  • Media
  • Investors